GlassScriptPhysician profile
Pedram Ilbeigi
NPI 1609827336
$13,018.41
in general payments reported to CMS, 2019-2025
35 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $253 · 2021: $646 · 2022: $1,551 · 2023: $3,858 · 2024: $4,935 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Education: $3,000 · Travel and Lodging: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,711.19 |
| Education | $3,000.00 |
| Travel and Lodging | $2,298.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,701.40 | 2023-2024 | Da Vinci Surgical System |
| Abbott Laboratories | $1,902.41 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,416.74 | 2019-2025 | Ams 700, Rezum Generator, Ams 800 Artificial Urinary Sphincter |
| Medtronic, INC. | $631.94 | 2021-2025 | Interstim |
| Procept Biorobotics Corporation | $575.21 | 2022 | |
| Axonics, INC. | $473.17 | 2022-2024 | Axonics |
| Teleflex LLC | $271.47 | 2023-2025 | Solesta, Barrigel, Urolift |
| Palette Life Sciences, INC. | $195.54 | 2023 | |
| Calyxo, INC. | $195.09 | 2024 | Cvac Aspiration System |
| Coloplast Corp | $170.89 | 2021-2024 | Titan |
| Laborie Medical Technologies Corp. | $166.83 | 2020-2023 | |
| Neotract INC. | $149.99 | 2019 | |
| Rochester Medical Corporation | $138.65 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $125.00 | 2025 | |
| Novo Nordisk INC | $118.46 | 2024 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urocure LLC | $109.35 | 2021 | |
| Abbvie INC. | $108.73 | 2019-2024 | |
| Hollister Incorporated | $67.81 | 2021-2022 | |
| Astellas Pharma US INC | $64.21 | 2019-2021 | |
| Pfizer INC. | $61.79 | 2019-2022 | |
| Urogen Pharma, INC. | $55.28 | 2022-2023 | Jelmyto |
| Biotronik Nro, INC. | $47.32 | 2025 | Prospera |
| Sumitomo Pharma America, INC. | $31.86 | 2025 | Orgovyx |
| Janssen Biotech, INC. | $29.97 | 2019-2020 | |
| Blue Earth Diagnostics | $25.04 | 2024 | |
| Immunitybio, INC. | $24.54 | 2025 | |
| Angiodynamics, INC. | $23.61 | 2021 | |
| Telix Pharmaceuticals | $21.88 | 2024 | Illuccix |
| Myovant Sciences INC. | $21.32 | 2022 | |
| Endo Pharmaceuticals INC. | $21.12 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.50 | 2019 | |
| Olympus America INC. | $14.76 | 2024 | Itind System |
| Metuchen Pharmaceuticals | $14.08 | 2019 | |
| Medtronic USA, INC. | $13.93 | 2020 | |
| Avion Pharmaceuticals | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Ilbeigi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.